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clinical diagnosis of the infection is suspected, if the 
negative bottles to maximize detection of the micro- 
organism. This procedure is time-consuming, expen- 
sive and poses a potential threat to the laboratory 
technicians while they are subculturing the bottles. As 
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All acellular pertussis vaccines include detoxified 
pertussis toxin; some also include filamentous hemag- 
glutinin (FHA), pertactin and/or fimbriae (agglutino- 
gens). Pertussis toxin (PT) is an extracellular toxin of 
Bovdetella pevtussis, while FHA and pertactin are 
immunogenic surface proteins of the organism. Almost 
all patients with pertussis have a serum antibody 
response to PT and FHA, and a majority also to 
pertactin [1,2], and recent data indicate that protection 
against pertussis is related to serum antibodies against 
PT and pertactin [ 3 ] .  PT is specific for B. pertussis, 
while FHA and pertactin are present also in B. 
parapertussis [4,5]. 
It was recently shown that non-encapsulated 
Haemophilus inzuenzae has surface proteins which cross- 
react with FHA of €3. pertussis [6] .  This led to the 
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question of whether antibodies against FHA can be 
induced by non-encapsulated Haemopkilus injuenzae, 
which belongs to the normal upper respiratory tract 
flora of pre-school children [7]. In a previous study, 
Swedish children had significant increases in FHA IgG, 
and also in pertactin IgG, during the second and third 
years of life, even though they had not had symptoms 
of pertussis [8]. This indicates that antibodies to these 
proteins are not specific for bordetella infections. The 
children were, however, vaccinated with an acellular 
pertussis vaccine consisting of pertussis toxoid alone, 
and it cannot be excluded that contact with B. pertussis 
in vaccinated children leads to asymptomatic infection 
with antibody responses to surface proteins, especially 
since pertussis was endemic in Sweden at the time. 
A study with measurement of FHA and pertactin 
IgG in children who, in contrast to the previous study 
[8], had never received any pertussis vaccine, is 
therefore reported here. Since the children were not 
vaccinated against pertussis, the absence of serum PT 
IgG could be used to identify those who had never 
been in contact with B. pertussis. The aim was to see if 
there is a natural acquisition, unrelated to bordetella 
infection, of FHA and pertactin antibodies. 
The sera were obtained from Swedish children, 
who participated in two studies of Haemophilus irlfluenzae 
type b (Hib) conjugate vaccines between 1987 and 
1994 [9-121. In both studies the children were 
vaccinated at 3, 5 and 12 months of age against Hib, 
diphtheria, tetanus and polio, and sera were obtained at 
3,4,6,12,13 and 30 months ofage. In the second study 
a serum sample was also obtained at 6 years of age. 
In the first study, 71 children received the Hib 
vaccine conjugated to an outer-membrane protein 
complex of Neisseria meningitidis group B [9,10]. When 
the originally planned assays had been performed, there 
were sufficient amounts of serum to determine IgG 
antibodies against PT, FHA and pertactin in four 
sera obtained at 3, 5 or 6, 12 or 13, and 30 months from 
58 children. Forty-four (76%) had non-detectable 
(<1 unit/mL) PT IgG in the sera obtained at 12-13 and 
30 months and were therefore considered not to have 
been in contact with B. pertussis. These 44 children are 
included in this study. PT IgG antibodies in the sera 
obtained at 3 and 5-6 months were considered to be of 
maternal origin. 
In the second study, 85 children were vaccinated 
with a Hib-tetanus toxoid conjugate [ll-121. Only 
sera obtained at 12 or 13 months, 30 months and 6 
years of age were assayed in the present study. There 
were sufficient amounts of serum to determine IgG 
against PT, FHA and pertactin in all three sera from 24 
children. Of those, 14 (58%) had PT IgG <1 unit/mL 
in all three sera and are included in this study. 
Serum IgG against PT, FHA and pertactin were 
estimated with enzyme-linked immunosorbent assay 
(ELISA) [13,14]. All sera from the same child were 
assayed on the same plate. Pertussis toxin was obtained 
from North American Vaccine, Beltsville, MD, USA. 
FHA was obtained from Institut Pasteur-Mtriux, 
Marcy l’Etoile, France. Pertactin was obtained from Dr 
Rino Rappuoli, Chiron Vaccines, Siena, Italy. The 
reference sera used were the United States Food and 
Drug Administration reference pertussis antisera Lot 3 
(for PT and FHA) and Lot 4 (for pertactin). Antibody 
concentrations were calculated from the reference 
line assay [15]. Minimum levels of detection were 
1 unit/mL for PT and FHA IgG and 2 units/mL for 
pertactin IgG. 
Antibody concentrations at different ages were 
compared with the two-tailed Wilcoxon’s signed rank 
test. Proportions of children with detectable antibodies 
at different ages were compared with the two-tailed 
Sign test. 
The vaccine trials were approved by the Ethics 
Committe, Goteborg University, and by the Medical 
Products Agency, Uppsala, Sweden. All parents gave 
oral consent after receiving written and oral infor- 
mation. 
Table 1 shows FHA and pertactin IgG in the 44 
children from whom four sera were obtained between 
3 and 30 months of age. FHA IgG of presumed 
maternal origin was found in all children at 3 months 
of age. Small but significant increases were seen between 
12-13 and 30 months of age. Pertactin antibodies were 
below or just above the level of detection in almost all 
sera at all ages. Of the 44 children, 20 had 22-fold 
increases in FHA IgG and 10 in pertactin IgG. 
Table 2 shows FHA and pertactin IgG in 14 
children between 12-13 months and 6 years of age. 
Significant increases in antibodies against both antigens 
were seen. Of the 14 children, 11 had >%fold increases 
in FHA IgG and eight in pertactin IgG. 
This study confirms the results of a previous study 
demonstrating that small but significant increases in 
FHA IgG and in pertactin IgG occur with increasing 
age and seem to be unrelated to contact with B. pertussis 
[8]. The absence of PT IgG in non-vaccinated children 
in this study does not prove that they had not had 
pertussis, but since infection with B. perfussis without 
development of PT antibodies is a very rare pheno- 
menon [1,2,16], we consider the absence of PT IgG 
strong evidence that these children had not been in 
contact with B. pertussis. 
The finding that FHA IgG serum antibodies may 
be acquired by other mechanisms than through contact 
with B. pertussis agrees with results of two previous 
Swedish studies, comparing the history of pertussis in 
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Table 1 Serum IgG against filamentous hemagglutinin and pertactin (units/mL) at different ages in 44 children who were 
not vaccinated against pertussis and who had not had pertussis (as defined by serum IgG against pertussis toxin <1 unit/niL 
in sera obtained at 13-13 and 30 months of age) 
Age Antibodies against: 
FHA Pertactin 
Detectable Range Median 
antibodies 
(21 unit/mL) 
Detectable Range Median 
antibodies 
( 2 2  units/mL) 
3 months 44/44 1 3 7  7.2" 
5-6 months 12/44 <1-98 3 . 5 h  
12-13 months 38/44 <1-38 2.0' 
30 months 42/44 <136.5  5.0d 
11/44 <1-71.8 <2 
16/44 <2-15.0 < 2  
13/44 <2-13.3 ( 2  
19/44 <2-18.4 <2 
a versus b, p<O.O01; h versus ', p<0.05; cversus d; p<0.01, by Wilcoxon's signed rank test. 
Table 2 Serum antibodies against filamentous hemagglutinin and pertactin (units/mL) at different ages in 14 children who 
were not vaccinated against pertussis and who had not had pertussis (as defined by serum IgG against pertussis toxin 
< 1 unit/niL in all sera) 
Antibodes against. 
FHA Pertactin 
Detectable Range Median 
antibodies 
(2 1 unit/mL) 
Detectable Range Median 
antibodies 
( 2 2  units/mL) 
12-13 months 7/14 < 1-24 1.8 3/14 <2-7.4 <2 
30 months 5/14" <1-59 <1< 3/14 12-8.3 < 2 e  
6 years 14/14h 4-115 11 .Od 9/14 <1-14.5 6.8' 
a versus h; p<0.01 by Sign test; versus ', versus '; ~ 4 . 0 5  by Wilcoxon's signed rank test. 
children (based on interviews with parents) with the 
presence of serum antibodies against P T  and FHA 
[17-181. Both studies found a good correlation between 
a history of pertussis and P T  antibodies. There were 
also significant correlations between a history of pertussis 
and FHA antibodies, but a considerable number of 
children in both studies had FHA antibodies even 
though they had no history of pertussis and no P T  
antibodes [17,18]. 
It should be emphasized that the results of the 
present and previous studies [8,17,18] must not be 
misinterpreted to discourage the use of FHA antibody 
determinations in paired sera for the diagnosis of 
pertussis. The antibody levels seen in the convalescent 
phase of pertussis are usually much higher than seen in 
the present study. In a study of 332 children with 
pertussis diagnosed serologically at the same laboratory 
as used in the present study, the median FHA IgG rise 
was 68-fold and the median level in the convalescent 
phase serum was 136 units/mL, i.e. more than 10 times 
higher than seen in 6-year-old children in the present 
study [16]. 
The present and a previous study [8] cannot answer 
the question of the origin of these serum FHA and 
pertactin antibodies. There is a possibility that they are 
derived from asymptomatic or unrecognized infection 
with B. parapertussir. This organism is, however, very 
uncommon in the Goteborg area, where less than 2% 
of all Bordetellu isolates are B. parupertussis [8, 191. 
Another possibility could be that infection with organ- 
isms with surface proteins similar to FHA and pertactin 
induce cross-reactive antibodies. Such an organism 
could be non-encapsulated Haemoplzilcrs inJ4uenzae, 
which has surface proteins similar to FHA [6]. To our 
knowledge, no organisms with surface proteins cross- 
reacting with pertactin have been identified. 
In conclusion, children acquire antibodies against 
two components of acellular pertussis vaccines, FHA 
and pertactin, even though there is evidence that they 
have not been in contact with B. pertussis or pertussis 
vaccines. This must be considered in immunogenicity 
studies of acellular pertussis vaccines containing these 
components, in particular if the antibody levels are 
followed for many years after vaccination, and also in 
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epidemiologic studies of bordetella infections using 
these antibodies as serologic markers. 
Antibodies against Huemophilus injuenzae type b and tetanus in 
infants after subcutaneous vaccination with PRP-T/diphtheria, 
or PRP-OMP/diphtheria-tetanus vaccines. Pediatr Infect Dis J 
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